Cargando…
Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug
It is increasingly suggested that ecological and evolutionary sciences could inspire novel therapies against cancer but medical evidence of this remains scarce at the moment. The Achilles heel of conventional and targeted anticancer treatments is intrinsic or acquired resistance following Darwinian...
Autores principales: | Girard, Pierre‐Marie, Berthault, Nathalie, Kozlac, Maria, Ferreira, Sofia, Jdey, Wael, Bhaskara, Srividya, Alekseev, Sergey, Thomas, Frederic, Dutreix, Marie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428804/ https://www.ncbi.nlm.nih.gov/pubmed/32821277 http://dx.doi.org/10.1111/eva.12949 |
Ejemplares similares
-
AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance()()
por: Jdey, Wael, et al.
Publicado: (2019) -
Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA
por: Berthault, Nathalie, et al.
Publicado: (2022) -
Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
por: Herath, Nirmitha I., et al.
Publicado: (2019) -
Effect of DNA repair inhibitor AsiDNA on the incidence of telomere fusion in crisis
por: Subecz, Chloé, et al.
Publicado: (2021) -
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
por: Le Tourneau, Christophe, et al.
Publicado: (2020)